Acetazolamide (All indications)

Small for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16074
R66706		 Christensen (Acetazolamide) (All indications) (Controls exposed to LTG), 2024 Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.14 [0.66;1.96] C
excluded (control group) 		15/127   920/8,756 935 127
ref
S16046
R66600		 Christensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.00 [0.58;1.73] 15/127   446,267/4,467,848 446,282 127
ref
Total 1 studies 1.00 [0.58;1.73] 446,282 127
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024Christensen, 2024 1 1.00[0.58; 1.73]446,2821270%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.52.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Acetazolamide) (All indications) (Controls unexposed, general population;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.00[0.58; 1.73]446,282127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.00[0.58; 1.73]446,282127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 Tags Adjustment   - Yes  - Yes 1.00[0.58; 1.73]446,282127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 All studiesAll studies 1.00[0.58; 1.73]446,282127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 10.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16074

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.58; 1.73]446,282127 -NAChristensen (Acetazolamide) (All indications) (Controls unexposed, general population), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.14[0.66; 1.96]935127 -NAChristensen (Acetazolamide) (All indications) (Controls exposed to LTG), 2024 10.510.01.0